Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: Pyrroloquinoline quinone promotes human mesenchymal stem cell-derived mitochondria to improve premature ovarian insufficiency in mice through the SIRT1/ATM/p53 pathway

Fig. 5

The mechanism of action for MSC-Mito therapy in conjunction with PQQ in chemotherapy-induced POI is as follows: PQQ facilitates MSC-Mito proliferation in cells and, in synergy with MSC-Mito, mitigates the elevated ROS levels induced by chemotherapy, thereby reducing mitochondrial damage. Simultaneously, this enhances the expression of SIRT1, upregulates TERF2 to promote DNA damage repair, suppresses ATM/p53 pathway activation, and reduces cellular apoptosis. Furthermore, SIRT1 upregulates PGC-1α, promoting mitochondrial biogenesis and maintaining cellular homeostasis

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512